Figure 3
From: A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
Relative change from baseline in target lesion size (at best tumour response). Shown is the per cent change of the lowest sum of the target lesions from baseline for patients who were on treatment for ⩾16 weeks. Seven patients had documented FGFR genetic alterations.
